| Madison Nicole Clark, OTR/L | |
|
360 Meadowlark Dr, Calhoun, KY 42327-9671 | |
| (270) 499-0663 | |
| Not Available |
| Full Name | Madison Nicole Clark |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 360 Meadowlark Dr, Calhoun, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1972200780 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Madison Nicole Clark, OTR/L 360 Meadowlark Dr, Calhoun, KY 42327-9671 Ph: (270) 499-0663 | Madison Nicole Clark, OTR/L 360 Meadowlark Dr, Calhoun, KY 42327-9671 Ph: (270) 499-0663 |
News Archive
Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that its New Drug Application (NDA) submitted on December 2, 2009 to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, has received an FDA PDUFA date of October 3, 2010. This NDA review is in support of US marketing approval and registration of Dyloject for the management of acute moderate-to-severe pain in adults.
Researchers from RCSI (Royal College of Surgeons in Ireland) and the University of Nice, France, have discovered the function of a gene called KCNQ1 that is directly related to the survival of colon cancer patients.
The Human Immunodeficiency Virus (HIV) is a highly contagious infection usually transmitted through body fluids during sexual contact, blood transfusion, during pregnancy, delivery, and breastfeeding through breast milk. Worldwide, there were about 37.9 million people across the globe with HIV in 2018, and approximately 1.7 million people became newly infected across the globe in 2018 alone.
The Gateway for Cancer Research announces an exciting new Gateway-funded phase II study using ADAPT therapy for treatment of metastatic colorectal cancer based on a 2010 AACR presentation by Dr. Lin and his collaborators.
Most people at high risk of overdose in Vancouver's Downtown Eastside who use cannabis do so for pain relief and other therapeutic reasons-and they may be at lower risk of overdosing on opioids as a result, suggests new research published in the peer-reviewed journal PLOS ONE.
› Verified 3 days ago